Please assess the completion status of the following clinical trial:

Trial Title: Allopurinol in Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* angiographically documented coronary artery disease,~* a positive exercise tolerance test (ETT)~* a history of symptoms of chronic, stable, effort-induced angina for ≥ 2 months.~* All concomitant antianginal medication will be allowed and continued unchanged during the study.~Exclusion Criteria:~* the inability to do an ETT due to back or leg problems,~* myocardial infarction or acute coronary syndrome ≤ 2 months,~* coronary revascularization (percutaneous or CABG) ≤ 6 months,~* Left Ventricular Ejection Fraction \<45%,~* estimated GFR \<60 ml/min or creatinine \>180 mmol/ml,~* significant valvular pathology,~* already had gout or on allopurinol,~* atrial arrhythmias or ECG abnormalities interfering with ST-segment interpretation,~* previous ventricular arrhythmias on ETT,~* severe hepatic disease~* or on azathioprine, 6 mercaptopurine or warfarin.~* Patients who have participated in any other clinical trial within the previous 30 days will be excluded.~* Patients who are unable to give informed consent will also be excluded from this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Allopurinol High dose (Type: EXPERIMENTAL): None
- Allopurinol Low dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).